Navigation Links
Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
Date:10/24/2007

BERKELEY HEIGHTS, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that clinical data from the Company's programs for Genasense(R) (oblimersen) in patients with advanced melanoma will be featured at the 4th International Melanoma Congress. The conference will take place at the New York Marriott Financial Center Hotel, New York, NY from November 1-4, 2007. A poster session featuring the Genasense data will take place on Thursday November 1 from 8-10 am EDT.

Titles and authors include the following:

Progression-free survival (PFS) with an oblimersen-dacarbazine regimen in advanced melanoma: PFS difference is not explained by assessment asymmetry. Presenter: E. Gilles.

Overview of the AGENDA Study: A randomized, double-blind study of Genasense plus dacarbazine in chemotherapy-naive patients with advanced melanoma and low LDH. Presenter: A. Bedikian.

A Phase I study of the triple combination of oblimersen, temozolomide, and Abraxane in patients with advanced melanoma and normal LDH. Presenter: A. Pavlick.

Pharmacokinetics of oblimersen in combination with dacarbazine in metastatic melanoma: randomized intra-subject evaluation. Presenter: D. Kerob.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversif
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... FORT MYERS, Fla. , Jan. 23, 2015  Today ... approval of Novartis, Bexsero® for the prevention of ... to 25. Bexsero and Pfizer,s vaccine Trumenba®, which received ... in helping prevent this devastating disease. ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) ... health care leaders and a new study analyzing the impact of ... is a nationwide coalition working to educate policy makers and the ... the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... 2015 More than a third of reproductive-aged women enrolled ... private insurance, filled a prescription for an opioid pain medication ... week,s Morbidity and Mortality Weekly Report (MMWR). ... moderate to severe pain.  They are also found in some ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... , , ROCKVILLE, Md., ... tissue proteomic analysis, today announced Mayo Clinic has ... patent for use in diagnosis of systemic amyloidosis ... enables solubilization of proteins for mass spectrometric analysis ...
... , NEW ... a new market research report is available ... Russian, Indian and Chinese Markets for Endoscopic ... http://www.reportlinker.com/p0164164/Brazil-Russian-Indian-and-Chinese-Markets-for-Endoscopic-Devices-2009-(4-Countries ).html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , The ...
Cached Medicine Technology:Liquid Tissue(R) Patent Licensed for Amyloidosis Proteomic Assay 2Reportlinker Adds Brazil, Russian, Indian and Chinese Markets for Endoscopic Devices 2009 (4 Countries) 2
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... , , , , NEW ... make a New Year,s resolution this year. Losing weight and developing healthy ... common goals. Historically, 30% of resolutions are broken in the first week ... committed to adopting healthier habits in 2010, The Biggest Loser Resort at ...
... , IDAHO FALLS, Idaho, Dec. 31 International Isotopes ... its license application to the U. S. Nuclear Regulatory ... extraction processing facility. , Steve T. Laflin, President and ... another significant accomplishment for the Company and is the ...
... , ... a mom shows that Narconon brought another family together for the holidays , ... (PRWEB) December 31, 2009 -- Celebrating the ... received another life changing success story evoking the true spirit of the holidays. "Before ...
... habit? Just in time for New Year,s resolutions, a ... to increase one,s risk for age-related macular degeneration (AMD), the ... The American Journal of Ophthalmology publishes the ... that it,s never too late to quit smoking," said lead ...
... the Streptococcus pneumoniae in samples that can ... predict risk of severe disease in H1N1 pandemic influenza. ... with higher morbidity and mortality than in other countries ... (CII) at the Mailman School of Public Health of ...
... ... Iceland, December 30 deCODE,genetics, Inc. (Nasdaq: DCGN ) today announced ... stating that for 30 consecutive,business days the market value of the ... the minimum level required for continued,listing on The Nasdaq Global Market ...
Cached Medicine News:Health News:Healthy, Delicious Recipes and Tips From the Biggest Loser Resort Help Celebrate a New Year and a New You 2Health News:Healthy, Delicious Recipes and Tips From the Biggest Loser Resort Help Celebrate a New Year and a New You 3Health News:International Isotopes Inc. Announces Submission of the License Application for Their Uranium De-conversion and Fluorine Extraction Processing Facility 2Health News:International Isotopes Inc. Announces Submission of the License Application for Their Uranium De-conversion and Fluorine Extraction Processing Facility 3Health News:Mother and Son Spend Holidays Free of Drug Addiction 2Health News:It's never too late to quit smoking and save your vision 2Health News:Severity of H1N1 influenza linked to presence of Streptococcus pneumoniae 2Health News:deCODE Receives Nasdaq Deficiency Notice 2Health News:deCODE Receives Nasdaq Deficiency Notice 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: